Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

Franck Emmanuel Nicolini, Grzegorz W. Basak, Simona Soverini, Giovanni Martinelli, Michael J. Mauro, Martin C. Müller, Andreas Hochhaus, Charles Chuah, Inge H. Dufva, Giovanna Rege-Cambrin, Giuseppe Saglio, Mauricette Michallet, Hélène Labussière, Stéphane Morisset, Sandrine Hayette, Gabriel Etienne, Eduardo Olavarria, Wei Zhou, Senaka Peter, Jane F. ApperleyJorge Cortes

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)5697-5700
Number of pages4
JournalBlood
Volume118
Issue number20
DOIs
StatePublished - Nov 17 2011
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias'. Together they form a unique fingerprint.

  • Cite this

    Nicolini, F. E., Basak, G. W., Soverini, S., Martinelli, G., Mauro, M. J., Müller, M. C., Hochhaus, A., Chuah, C., Dufva, I. H., Rege-Cambrin, G., Saglio, G., Michallet, M., Labussière, H., Morisset, S., Hayette, S., Etienne, G., Olavarria, E., Zhou, W., Peter, S., ... Cortes, J. (2011). Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood, 118(20), 5697-5700. https://doi.org/10.1182/blood-2011-07-367326